Compare Biogen Inc (BIIB) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SPDR Gold Trust — how do they compare? Biogen Inc trades at $206.79 (market cap $30.13B), while SPDR Gold Trust trades at $404.87. The key difference: Biogen Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| BIIB | GLD | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | — |
52-Week High | $216.63 | $495.90 |
52-Week Low | $128.93 | $305.27 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
GLD, the SPDR Gold Shares ETF, trades at $405.25, up 0.65% today, reflecting strong momentum as gold benefits from cooling U.S. inflation data and safe-haven demand. The technical outlook is bullish with moving averages supporting upward trends, though oscillators signal overbought conditions. Recent news highlights gold's resilience amid geopolitical tensions and central bank buying, with spot gold surpassing $4,438 per ounce after July's CPI report showed a 2.5% annual core increase (Kitco, 2026-08-12).
The outlook for GLD remains positive driven by macroeconomic support, but risks include potential Fed policy shifts and profit-taking pressure. Investors may see opportunities in gold's role as a hedge, though high RSI levels suggest near-term volatility. Key resistance at $407 could test further gains, while support lies at $396.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
